District Of Columbia is currently home to 853 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Washington, Washington, D.C., Washington DC and Washington, Dc. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Feasibility and Efficacy of Attentional-Control Training in Sickle Cell Disease
NCT05099874
Recruiting
Children with sickle cell disease (SCD) exhibit significantly reduced cognitive functioning (often difficulties with attention) compared to peers and siblings without SCD. EndeavorRx (Akili Interactive Labs: Boston, MA) is an FDA-approved home-based, electronic attentional-control training program designed to treat attention problems in youth. Users access EndeavorRx on a tablet device for 25-30 minutes each day, 5 days per week, for 4 weeks. The program involves training in a game-like environm... Read More
Gender:
ALL
Ages:
Between 8 years and 16 years
Trial Updated:
01/08/2025
Locations: Children's National Hospital, Washington, District of Columbia
Conditions: Sickle Cell Disease, Attention Deficit, Cognitive Deficit in Attention
Register for Updates
Pregnancy and Early Neurodevelopmental Outcomes Following In Utero Lyme Disease Exposure
NCT06026969
Recruiting
The purpose of this pilot study is to assess the feasibility of longitudinal neurodevelopmental evaluation of fetuses and infants exposed to Lyme disease in utero. Participants with Lyme disease or Post-Treatment Lyme Disease Syndrome (PTLDS) will be recruited during pregnancy. Pregnancies will be monitored and infant development will be assessed from birth until age 18 months.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/06/2025
Locations: Children's National Hospital, Washington, District of Columbia
Conditions: Lyme Disease, Post-Treatment Lyme Disease, Chronic Lyme Disease, Tick-Borne Infections, Pregnancy Complications, Child Development
Register for Updates
Multi-Center Molecular Diagnosis and Host Response of Respiratory Viral Infections in Pediatric Transplant Recipients
NCT05550298
Recruiting
The participants are being asked to take part in this clinical trial, a type of research study, because the participants are scheduled to receive or have recently received a hematopoietic cell transplant (HCT) or a solid organ transplant (SOT). Primary Objective To determine if pre-transplant screening for respiratory viral load predicts RVI within 1- year post-transplant among survivors. Secondary Objectives: * To develop and validate a classifier based on pre-transplant immunological profi... Read More
Gender:
ALL
Ages:
18 years and below
Trial Updated:
01/06/2025
Locations: Children's National Medical, Washington, District of Columbia
Conditions: Hematopoietic Cell Transplant, Solid Organ Transplant, Respiratory Viral Infection
Register for Updates
A Study of NST-6179 in Subjects With Intestinal Failure-Associated Liver Disease (IFALD).
NCT05919680
Recruiting
This is a phase 2a, multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of NST-6179 in subjects with intestinal failure-associated liver disease (IFALD) receiving parenteral nutrition (PN). The study will be conducted in 2 sequential parts. Up to 36 subjects diagnosed with IFALD will be enrolled in the study, of which up to 18 subjects will be enrolled in each of the 2 parts and randomized (2:1) t... Read More
Gender:
ALL
Ages:
16 years and above
Trial Updated:
01/05/2025
Locations: MedStar Georgetown University Hospital, Washington, District of Columbia
Conditions: Intestinal Failure Associated Liver Disease
Register for Updates
NPWT Reduction Mammaplasty
NCT06725459
Recruiting
In this prospective, randomized, split-body control trial, we aim to compare complications, patient-reported outcomes, and cost differentials following reduction mammaplasty with prophylactic closed incision negative pressure wound therapy versus standard adhesive dressing.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
01/03/2025
Locations: Medstar Georgetown University Hospital, Washington, District of Columbia
Conditions: Healthy, Macromastia, Negative Pressure Therapy, Mammaplasty, Wound Healing
Register for Updates
CtDNA Based MRD Testing for NAC Monitoring in TNBC
NCT06230185
Recruiting
A prospective, multicenter, observational study to evaluate the correlation of Molecular Residual Disease (MRD) detection using circulating tumor DNA guided test to pathological complete response (pCR) after neoadjuvant chemotherapy (NAC) in stage I-III triple negative breast cancer (TNBC). Results from this study aim to improve MRD detection and disease outcomes for future patients.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
01/03/2025
Locations: George Washington University, Washington DC, District of Columbia
Conditions: TNBC - Triple-Negative Breast Cancer, Minimal Residual Disease
Register for Updates
Multi Tumor-Associated Antigen-Specific T Lymphocytes to Treat Patients with High Risk Solid Tumors
NCT05238792
Recruiting
This is a phase I dose-escalation study to evaluate the safety of partially human leukocyte antigen (HLA)-matched multi tumor-associated antigen-specific T cell (TAA-T) therapy for patients with high-risk solid tumors due to the presence of refractory, relapsed and/or minimal residual detectable disease following conventional therapy. Conventional therapy may include chemotherapy, surgery, radiation, autologous stem cell transplant, or targeted therapy.
Gender:
ALL
Ages:
Between 6 years and 70 years
Trial Updated:
12/30/2024
Locations: Children's National Hospital, Washington, District of Columbia
Conditions: Solid Tumor
Register for Updates
Target ALS Biomarker Study; Longitudinal Biofluids, Clinical Measures, and At Home Measures
NCT05137665
Recruiting
The goal of the study is to generate a biorepository of longitudinal biofluids-blood (plasma and serum), cerebral spinal fluid (CSF) and urine linked to genetics and longitudinal clinical information that are made available to the research community. To accomplish these goals, we will enroll 800 Amyotrophic Lateral Sclerosis (ALS) patients and 200 healthy controls from sites globally, over a 5 year time frame. Additionally, speech and motor function and spirometry measures will be collected bi-w... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/26/2024
Locations: Georgetown University, Georgetown, District of Columbia
Conditions: Amyotrophic Lateral Sclerosis, Movement Disorders, Degenerative Disorder, Motor Neuron Disease
Register for Updates
A Patient and Provider Intervention to Address Health Disparities in Lung Cancer Screening
NCT04675476
Recruiting
To test the impact of a multilevel intervention on primary (provider-patient communication, intentions, and knowledge) and secondary (screening referrals and completion) outcomes.
Gender:
ALL
Ages:
Between 50 years and 80 years
Trial Updated:
12/23/2024
Locations: MedStar Health, Washington, District of Columbia
Conditions: Lung Cancer
Register for Updates
Safety and Efficacy Study of Intracystic TARA-002 for the Treatment of Lymphatic Malformations in Participants 6 Months to Less Than 18 Years of Age
NCT05871970
Recruiting
This is a Phase 2a/b single arm open label study to evaluate the safety, reactogenicity, and efficacy of intracystic injection of TARA-002 in participants 6 months to less than 18 years of age for the treatment of macrocystic and mixed cystic lymphatic malformations. The Phase 2a safety lead-in, age de-escalation study is designed to establish the safety of TARA-002 in older participants 6 years to less than 18 years before proceeding to younger participants 2 years to less than 6 years, then 6... Read More
Gender:
ALL
Ages:
Between 6 months and 18 years
Trial Updated:
12/20/2024
Locations: Children's National Medical Center: Children's Research Institute, Washington, District of Columbia
Conditions: Lymphatic Malformation
Register for Updates
Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic NOH in Participants with Multiple System Atrophy
NCT05696717
Recruiting
This is a Phase 3, multi-center, randomized withdrawal study to evaluate the efficacy and durability of ampreloxetine in participants with MSA and symptomatic nOH after 20 weeks of treatment. This study includes 4 periods: Screening, open label, randomized withdrawal, and long-term treatment extension (LTE).
Gender:
ALL
Ages:
30 years and above
Trial Updated:
12/20/2024
Locations: Medstar Georgetown University Hospital, Washington DC, District of Columbia
Conditions: Symptomatic Neurogenic Orthostatic Hypotension, MSA - Multiple System Atrophy
Register for Updates
Texts for Diabetes Control Among Homeless Persons
NCT05616026
Recruiting
This mixed method study includes a Randomized Controlled Trial (RCT) and qualitative methods to assess the impact of a SMS text strategy in diabetes control among persons who experience homelessness.
Gender:
ALL
Ages:
21 years and above
Trial Updated:
12/19/2024
Locations: George Washington University, Washington, District of Columbia
Conditions: Diabetes Mellitus
Register for Updates